Checkpoint Blockade in Cancer Immunotherapy

Por Korman, Alan J., Peggs, Karl S., Allison, James P.
Publicado em 2006

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more

Por Turnis, Meghan E., Korman, Alan J., Drake, Charles G., Vignali, Dario A.A.
Publicado em 2012

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

Por Peggs, Karl S., Quezada, Sergio A., Chambers, Cynthia A., Korman, Alan J., Allison, James P.
Publicado em 2009

Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011

Por Forero, Ivan Martinez, Okada, Hideho, Topalian, Suzanne L, Gajewski, Thomas F, Korman, Alan J, Melero, Ignacio
Publicado em 2012

Activation of innate and adaptive immunity as an effective combined strategy for cancer immunotherapy

Por Rakhmilevich, Alexander, Felder, Mildred, Lever, Lauren, Van De Voort, Tyler, Korman, Alan J, Gillies, Stephen D, Sondel, Paul M
Publicado no J Immunother Cancer (2015)

In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice

Por Palmer, Brent E., Neff, C. Preston, LeCureux, Jonathan, Ehler, Angelica, DSouza, Michelle, Remling-Mulder, Leila, Korman, Alan J., Fontenot, Andrew P., Akkina, Ramesh
Publicado em 2012

Accelerated autoimmune diabetes in the absence of LAG-3

Por Bettini, Maria, Szymczak-Workman, Andrea L., Forbes, Karen, Castellaw, Ashley H., Selby, Mark, Pan, Xiaoyu, Drake, Charles G., Korman, Alan J., Vignali, Dario A.A.
Publicado em 2011

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis

Por Chang, Katherine C, Burnham, Carey-Ann, Compton, Stephanie M, Rasche, David P, Mazuski, RichardJ, SMcDonough, Jacquelyn, Unsinger, Jacqueline, Korman, Alan J, Green, Jonathan M, Hotchkiss, Richard S
Publicado em 2013

TIGIT and PD-1 impair tumor antigen–specific CD8(+) T cells in melanoma patients

Por Chauvin, Joe-Marc, Pagliano, Ornella, Fourcade, Julien, Sun, Zhaojun, Wang, Hong, Sander, Cindy, Kirkwood, John M., Chen, Tseng-hui Timothy, Maurer, Mark, Korman, Alan J., Zarour, Hassane M.
Publicado no J Clin Invest (2015)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab

Por Koguchi, Yoshinobu, Hoen, Helena, Bambina, Shelly, Rynning, Michael, Fuerstenberg, Richard, Feng, Zipei, Fox, Bernard, Bifulco, Carlo, Curti, Brendan D, Urba, Walter, Milburn, Christina, Korman, Alan J, Bahjat, Keith S
Publicado no J Immunother Cancer (2015)

Effective combination of innate and adaptive immunotherapeutic approaches in a mouse melanoma model

Por Rakhmilevich, Alexander L., Felder, Mildred, Lever, Lauren, Slowinski, Jacob, Rasmussen, Kayla, Hoefges, Anna, Van De Voort, Tyler J., Loibner, Hans, Korman, Alan J., Gillies, Stephen D., Sondel, Paul M.
Publicado no J Immunol (2017)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Por Wolchok, Jedd D, Hodi, F Stephen, Weber, Jeffrey S, Allison, James P, Urba, Walter J, Robert, Caroline, O'Day, Steven J, Hoos, Axel, Humphrey, Rachel, Berman, David M, Lonberg, Nils, Korman, Alan J
Publicado em 2013

Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model

Por Morris, Zachary S, Guy, Emily I, Francis, David M, Gressett, Monica M, Armstrong, Eric A, Huang, Shyhmin, Gillies, Stephen D, Korman, Alan J, Hank, Jacquelyn A, Rakhmilevich, Alexander L, Harari, Paul M, Sondel, Paul M
Publicado no J Immunother Cancer (2015)

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

Por Selby, Mark J., Engelhardt, John J., Johnston, Robert J., Lu, Li-Sheng, Han, Minhua, Thudium, Kent, Yao, Dapeng, Quigley, Michael, Valle, Jose, Wang, Changyu, Chen, Bing, Cardarelli, Pina M., Blanset, Diann, Korman, Alan J.
Publicado no PLoS One (2016)

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

Por Selby, Mark J., Engelhardt, John J., Johnston, Robert J., Lu, Li-Sheng, Han, Minhua, Thudium, Kent, Yao, Dapeng, Quigley, Michael, Valle, Jose, Wang, Changyu, Chen, Bing, Cardarelli, Pina M., Blanset, Diann, Korman, Alan J.
Publicado no PLoS One (2016)

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus...

Por Gardiner, David, Lalezari, Jay, Lawitz, Eric, DiMicco, Michael, Ghalib, Rheem, Reddy, K. Rajender, Chang, Kyong-Mi, Sulkowski, Mark, Marro, Steven O’, Anderson, Jeffrey, He, Bing, Kansra, Vikram, McPhee, Fiona, Wind-Rotolo, Megan, Grasela, Dennis, Selby, Mark, Korman, Alan J., Lowy, Israel
Publicado em 2013

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Por Brahmer, Julie R., Drake, Charles G., Wollner, Ira, Powderly, John D., Picus, Joel, Sharfman, William H., Stankevich, Elizabeth, Pons, Alice, Salay, Theresa M., McMiller, Tracee L., Gilson, Marta M., Wang, Changyu, Selby, Mark, Taube, Janis M., Anders, Robert, Chen, Lieping, Korman, Alan J., Pardoll, Drew M., Lowy, Israel, Topalian, Suzanne L.
Publicado no J Clin Oncol (2010)

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape

Por Woo, Seng-Ryong, Turnis, Meghan E., Goldberg, Monica V., Bankoti, Jaishree, Selby, Mark, Nirschl, Christopher J., Bettini, Matthew L., Gravano, David, Vogel, Peter, Liu, Chih Long, Tangsombatvisit, Stephanie, Grosso, Joseph F., Netto, George, Smeltzer, Matthew P., Chaux, Alcides, Utz, Paul J., Workman, Creg J., Pardoll, Drew M., Korman, Alan J., Drake, Charles G., Vignali, Dario A.A.
Publicado em 2011

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Por Callahan, Margaret K, Horak, Christine E, Curran, Michael A, Hollman, Travis, Schaer, David A, Yuan, Jianda, Lesokhin, Alexander M, Kitano, Shigehisa, Hong, Quan, Ariyan, Charlotte E, Busam, Klaus J, Feely, William, Jure-Kunkel, Maria, Grosso, Joseph, Simon, Jason S, Korman, Alan J, Wigginton, Jon M, Gupta, Ashok K, Zhang, Xiaoling, Phillips, Therese, Simmons, Pauline, Sznol, Mario, Wolchok, Jedd D
Publicado em 2013

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

Por Chew, Glen M., Fujita, Tsuyoshi, Webb, Gabriela M., Burwitz, Benjamin J., Wu, Helen L., Reed, Jason S., Hammond, Katherine B., Clayton, Kiera L., Ishii, Naoto, Abdel-Mohsen, Mohamed, Liegler, Teri, Mitchell, Brooks I., Hecht, Frederick M., Ostrowski, Mario, Shikuma, Cecilia M., Hansen, Scott G., Maurer, Mark, Korman, Alan J., Deeks, Steven G., Sacha, Jonah B., Ndhlovu, Lishomwa C.
Publicado no PLoS Pathog (2016)